Published in

National Academy of Sciences, Proceedings of the National Academy of Sciences, 35(104), p. 13881-13886, 2007

DOI: 10.1073/pnas.0706247104

Links

Tools

Export citation

Search in Google Scholar

The synthesis and in vitro testing of a zinc-activated MRI contrast agent

Journal article published in 2007 by Jody L., Jody L. Major, Giacomo Parigi, Claudio Luchinat ORCID, Thomas J. Meade
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Red circle
Preprint: archiving forbidden
Green circle
Postprint: archiving allowed
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

Zinc(II) plays a vital role in normal cellular function as an essential component of numerous enzymes, transcription factors, and synaptic vesicles. While zinc can be linked to a variety of physiological processes, the mechanisms of its cellular actions are less discernible. Here, we have synthesized and tested a Zn(II)-activated magnetic resonance imaging (MRI) contrast agent in which the coordination geometry of the complex rearranges upon binding of Zn(II). In the absence of Zn(II) water is restricted from binding to a chelated Gd(III) ion by coordinating acetate arms resulting in a low relaxivity of 2.33 mM −1 ·s −1 at 60 MHz. Upon addition of Zn(II) the relaxivity of the Gd(III)–Zn(II) complex increases to 5.07 mM −1 ·s −1 and is consistent with one water molecule bound to Gd(III). These results were confirmed by nuclear magnetic relaxation dispersion analysis. There was no observed change in relaxivity of the Gd(III) complex when physiologically competing cations Ca(II) and Mg(II) were added. A competitive binding assay gave a dissociation constant of 2.38 × 10 −4 M for the Gd(III)–Zn(II) complex. In vitro magnetic resonance images confirm that Zn(II) concentrations as low as 100 μM can be detected by using this contrast agent.